IRX-101 / Irenix Medical - LARVOL DELTA

SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF) (clinicaltrials.gov) - P2 | N=155 | Completed | Sponsor: iRenix Medical, Inc. | Recruiting ➔ Completed | N=75 ➔ 155 | Trial completion date: Aug 2024 ➔ Mar 2026

Enrollment change • Trial completion • Trial completion date • Ophthalmology • Pain • Retinal Disorders

COMFORT: Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections (clinicaltrials.gov) - P3 | N=240 | Not yet recruiting | Sponsor: iRenix Medical, Inc. | Trial completion date: Aug 2024 ➔ Dec 2027 | Trial primary completion date: Jun 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Ophthalmology • Pain • Retinal Disorders

SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF) (clinicaltrials.gov) - P2 | N=75 | Recruiting | Sponsor: iRenix Medical, Inc. | Phase classification: P3 ➔ P2 | N=240 ➔ 75

Enrollment change • Phase classification • Ophthalmology • Pain • Retinal Disorders

SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF) (clinicaltrials.gov) - P3 | N=240 | Recruiting | Sponsor: iRenix Medical, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Ophthalmology • Pain • Retinal Disorders

COMFORT: Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections (clinicaltrials.gov) - P3 | N=240 | Recruiting | Sponsor: iRenix Medical, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Ophthalmology • Pain • Retinal Disorders

COMFORT: Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections (clinicaltrials.gov) - P3 | N=240 | Not yet recruiting | Sponsor: iRenix Medical, Inc.

New P3 trial • Ophthalmology • Pain • Retinal Disorders

SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF) (clinicaltrials.gov) - P3 | N=500 | Not yet recruiting | Sponsor: iRenix Medical, Inc.

New P3 trial • Ophthalmology • Pain • Retinal Disorders